154 related articles for article (PubMed ID: 31651858)
1. CD56-chimeric antigen receptor T-cell therapy for refractory/recurrent rhabdomyosarcoma: A 3.5-year follow-up case report.
Jiang C; Zhao W; Qin M; Jin M; Chang L; Ma X
Medicine (Baltimore); 2019 Oct; 98(43):e17572. PubMed ID: 31651858
[TBL] [Abstract][Full Text] [Related]
2. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
3. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma.
Hegde M; Joseph SK; Pashankar F; DeRenzo C; Sanber K; Navai S; Byrd TT; Hicks J; Xu ML; Gerken C; Kalra M; Robertson C; Zhang H; Shree A; Mehta B; Dakhova O; Salsman VS; Grilley B; Gee A; Dotti G; Heslop HE; Brenner MK; Wels WS; Gottschalk S; Ahmed N
Nat Commun; 2020 Jul; 11(1):3549. PubMed ID: 32669548
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
5. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
[No Abstract] [Full Text] [Related]
6. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
Yagi Y; Kanemasa Y; Ohigashi A; Morita Y; Tamura T; Nakamura S; Otsuka Y; Kishida Y; Kageyama A; Shimizuguchi T; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Omuro Y; Shimoyama T
Medicine (Baltimore); 2021 Nov; 100(44):e27733. PubMed ID: 34871273
[TBL] [Abstract][Full Text] [Related]
8. [Adoptive T-cell therapy of rhabdomyosarcoma].
Simon-Keller K; Paschen A; Eichmüller S; Gattenlöhner S; Barth S; Koscielniak E; Leuschner I; Stöbel P; Hombach A; Abken H; Marx A
Pathologe; 2010 Oct; 31 Suppl 2():215-20. PubMed ID: 20730458
[TBL] [Abstract][Full Text] [Related]
9. CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models.
Timpanaro A; Piccand C; Dzhumashev D; Anton-Joseph S; Robbi A; Moser J; Rössler J; Bernasconi M
J Exp Clin Cancer Res; 2023 Nov; 42(1):293. PubMed ID: 37924157
[TBL] [Abstract][Full Text] [Related]
10. Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors Committee.
Rodeberg DA; Anderson JR; Arndt CA; Ferrer FA; Raney RB; Jenney ME; Brecht IB; Koscielniak E; Carli M; Bisogno G; Oberlin O; Rey A; Ullrich F; Stevens MC; Meyer WH
Int J Cancer; 2011 Mar; 128(5):1232-9. PubMed ID: 20473932
[TBL] [Abstract][Full Text] [Related]
11. Recurrence and treatment of adult primary nonmetastatic bladder rhabdomyosarcoma: A systematic review.
Nguyen A; Fassas S; Freidberg N; Sullo E; Whalen M
Urol Oncol; 2021 Nov; 39(11):774-780. PubMed ID: 34332845
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
13. Rhabdomyosarcoma of the urinary bladder and vagina: a clinicopathologic study with emphasis on recurrent disease: a report from the Kiel Pediatric Tumor Registry and the German CWS Study.
Leuschner I; Harms D; Mattke A; Koscielniak E; Treuner J
Am J Surg Pathol; 2001 Jul; 25(7):856-64. PubMed ID: 11420456
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients.
Zhang Y; Zhang Z; Ding Y; Fang Y; Wang P; Chu W; Jin Z; Yang X; Wang J; Lou J; Qian Q
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3725-3734. PubMed ID: 34032893
[TBL] [Abstract][Full Text] [Related]
15. CD4
Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
[TBL] [Abstract][Full Text] [Related]
16. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
[TBL] [Abstract][Full Text] [Related]
17. Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy.
Hu GH; Zhao XY; Zuo YX; Chang YJ; Suo P; Wu J; Jia YP; Lu AD; Li YC; Wang Y; Jiao SC; Zhang LJ; Kong J; Yan CH; Xu LP; Zhang XH; Liu KY; Cheng YF; Wang Y; Zhang LP; Huang XJ
Leukemia; 2021 Nov; 35(11):3092-3100. PubMed ID: 33824464
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of Chimeric Antigen Receptor T Cell in the Treatment of Refractory/Recurrent B Acute Lymphocytic Leukemia in Children].
Yang F; Wang TY; DU WW; He HL; Xiao PF; Lu Y; Hu SY; Li BS; Lu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):718-725. PubMed ID: 35680795
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor-modified T-cell therapy for platelet-derived growth factor receptor α-positive rhabdomyosarcoma.
Xiao W; Wang J; Wen X; Xu B; Que Y; Yu K; Xu L; Zhao J; Pan Q; Zhou P; Zhang X
Cancer; 2020 May; 126 Suppl 9():2093-2100. PubMed ID: 32293729
[TBL] [Abstract][Full Text] [Related]
20. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2021; 12():605766. PubMed ID: 34025637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
